Luye Claims A First With Chinese Denosumab Approval

Boan Biotech Subsidiary Sees Prolia Biosimilar Boyoubei Approved By China’s NMPA

 
• By Dave Wallace

Luye Pharma has claimed a world first after its Boan Biotech subsidiary obtained an approval from China’s NMPA for its Boyoubei denosumab biosimilar rival to Amgen’s Prolia.

Prolia pack injector
Luye’s biosimilar version of Prolia has been approved in China • Source: Shutterstock

More from Biosimilars

More from Products